title: Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite.
abstract: Inflammatory cytokines associated with atherosclerosis may be capable of stimulating the synthesis and activity of inducible nitric oxide synthase (iNOS), which could further influence the pathologic features associated with the disease. Although there is a certain amount of indirect evidence to support the presence of iNOS in atherosclerosis, there has been no definitive study to confirm this. This study has assessed the localization of iNOS within human normal and atherosclerotic vessels by immunocytochemistry, Western blotting, and in situ hybridization. Further, activity of NO synthase has been assessed by detection of nitrotyrosine, which is a marker indicative of the formation and activity of the nitric oxide-derived oxidant, peroxynitrite. In Western blots of crude homogenates of atherosclerotic aorta, the iNOS antiserum reacted with a band of approximately 130 kd (the known molecular weight for iNOS), but no such band was seen in normal aorta. Immunostaining and in situ hybridization confirmed the presence of iNOS in atherosclerotic vessels, in which it was specifically localized to (CD68-positive) macrophages, foam cells, and the vascular smooth muscle. The antiserum to nitrotyrosine reacted with a wide range of protein bands (approximately 180 to 30 kd) in Western blots of atherosclerotic aorta. The distribution of immunostaining for nitrotyrosine was virtually identical to that seen for iNOS and was present in macrophages, foam cells, and the vascular smooth muscle. In conclusion, these studies have demonstrated that stimulated expression of iNOS is associated with atherosclerosis and that the activity of this enzyme under such conditions preferentially promotes the formation and activity of peroxynitrite. This may be important in the pathology of atherosclerosis, which contributes to lipid peroxidation and to vascular damage.
authors.affiliation: Department of Histochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
authors.forename: L D
authors.initials: LD
authors.lastname: Buttery
authors.forename: D R
authors.initials: DR
authors.lastname: Springall
authors.forename: A H
authors.initials: AH
authors.lastname: Chester
authors.forename: T J
authors.initials: TJ
authors.lastname: Evans
authors.forename: E N
authors.initials: EN
authors.lastname: Standfield
authors.forename: D V
authors.initials: DV
authors.lastname: Parums
authors.forename: M H
authors.initials: MH
authors.lastname: Yacoub
authors.forename: J M
authors.initials: JM
authors.lastname: Polak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001161:Arteriosclerosis / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers / Q000032:analysis; D015153:Blotting, Western; D005260:Female; D005487:Foam Cells / Q000737:chemistry; D006801:Humans; D017403:In Situ Hybridization; D008264:Macrophages / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000737:chemistry; D009566:Nitrates / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D014443:Tyrosine / Q000031:analogs & derivatives
chemical_list: D015415:Biomarkers; D009566:Nitrates; D012333:RNA, Messenger; C039642:peroxynitric acid; D014443:Tyrosine; D019001:Nitric Oxide Synthase